

Press Release



ProStrakan Group plc

Alan Walker appointed to ProStrakan Board

Galashiels, Scotland – 24 January 2006 – ProStrakan Group plc, the European specialty pharmaceutical company, today announces the appointment of Alan Walker to the Board of the Company as an Executive Director. Alan has been Executive Vice-President of Global Commercial Operations with ProStrakan since 2001 (see full biography below).

Commenting on the appointment, Harry Stratford, Executive Chairman of ProStrakan, said: “Alan is a highly respected figure in the international pharmaceutical industry. Over the past five years, he has played a pivotal role in the overall growth of ProStrakan so that, today, we are one of the fastest growing healthcare companies in Europe. I look forward to his contribution to our future growth and success. It is a real pleasure to welcome him on to the Board.”

With reference to paragraphs 9.6.13 (1) – (6) of the FSA's Listing Rules, there are no disclosures required.

ENDS

Enquiries:

ProStrakan

Wilson Totten, Chief Executive Officer
Adrian Gardner, Chief Financial Officer
David Watt, Corp Comms

Tel: 01896 664000
Tel: 01896 664000
Tel: 01896 664103

Financial Dynamics

David Yates / Sarah Macleod

Tel: 020 7831 3113

Notes

Alan Walker

Alan Walker is a former UK Marketing Director of Parke Davis and a former Director of International Pharmaceutical Marketing with Warner Lambert at their headquarters in the US which led to his appointment as Managing Director of the Elan/Warner Lambert (UK/Ireland) joint venture. Before joining ProStrakan. Alan became Regional President of Parke Davis Pharmaceuticals in the UK and Scandinavia and, subsequently, Italy and Greece. He is a Fellow of the Chartered Institute of Marketing, a Fellow of the Institute of Directors and a Freeman of the City of London. A Vice-President of the Association of the British Pharmaceutical Industry from 1997 to 1999, he was re-appointed to the ABPI Board of Management in 2004. He became a Chartered Director in 2004.

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. The Company's therapeutic focus is on oncology supportive care, bone diseases, women's health and issues relating to the ageing male. Headquartered in Scotland, the Company's R&D facilities are situated in Romainville, near Paris, and in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are principally handled by commercial subsidiaries based in the UK, France, Germany and Spain.

ProStrakan floated on the London Stock Exchange in June 2005. In September 2005, the Group announced interim results showing revenues up 78% to £16.5 million.

www.prostrakan.com